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S U M M A R Y
We present a case of cardiac device-related Aspergillus endocarditis in a patient with a pacemaker and
an allogeneic bone marrow transplant to segue into a review of the Aspergillus endocarditis literature.
Aspergillus endocarditis should be suspected in patients with underlying immunosuppression, negative
cultures, and a vegetation on echocardiography. Diagnosis ultimately requires conﬁrmation by tissue
histology and culture. The optimal treatment approach often requires aggressive surgical debridement in
conjunction with prolonged antifungal therapy.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Aspergillus species have the ability to cause severe invasive
infections in almost every major organ system, including, but not
limited to, the sinuses and lungs, heart, and central nervous
system. Aspergillus most commonly infects immunocompromised
hosts in the respiratory tract. Aspergillus endocarditis and
Aspergillus implantable cardiac device-related infective endocar-
ditis (CDRIE) are uncommon.
Here we present a case of pacemaker-associated Aspergillus
fumigatus endocarditis in a host with an underlying hematological
malignancy, and follow this with a review of the literature and
discussion of the prevalence, predisposing factors, and diagnostic
and treatment modalities for Aspergillus endocarditis.
2. Case presentation
An 18-year-old Caucasian male, who had received an
allogeneic bone marrow transplant at age 5 years for acute
myeloid leukemia, presented with cyanotic spells, night sweats,
chills, and a 4.5 kgweight loss over 3months. Over the last several
months, he had experienced recurrent lower respiratory tract
infections, for which his hematologist had placed him on empiric,
monthly intravenous immunoglobulin infusions. He had under-* Corresponding author. Tel.: +1 313 598 8584; fax: +1 404 880 9305.
E-mail address: akalokh@emory.edu (A.S. Kalokhe).
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doi:10.1016/j.ijid.2010.08.005gone pacemaker placement for viral myocarditis at age 13 years,
with pacemaker device replacements due to malfunction at ages
14 and 15 years with retention of leads. In addition to
hypothyroidism and asthma, he had a past history of graft-
versus-host disease; a recent bone marrow biopsy revealed 5%
cellularity and cytogenetics suggesting an evolving myelodys-
plastic syndrome (MDS). Outpatient medications included cypro-
heptadine, levothyroxine, and montelukast. His only pets were
cats and dogs, and he reported no recent travel.
On admission, his temperature was 35.8 8C, he had a pulse of 75
beats per min, blood pressure of 86/55mmHg, and respiratory rate
of 18 breaths perminute. Heart soundswere regular, with a loud S1
and split S2, but nomurmurwas audible. No evidence of peripheral
or central cyanosis, clubbing, or peripheral stigmata of endocardi-
tis was found on physical examination. The pacemaker site was
without erythema, swelling, or tenderness.
Laboratory evaluation revealed normal chemistries and liver
enzymes. Thewhite blood cell countwas normal (9.9  109 cells/l),
but demonstrated a left shift (71% neutrophils and 13% bands). Low
hemoglobin (8.4 g/dl) and platelets (9  109/ml) were noted.
Multiple sets of blood cultures were obtained. A chest X-ray
demonstrated pacemaker leads in the right atrium and ventricle,
but no other abnormalities. Right bundle branch block and right
axis deviation was present on electrocardiogram (ECG). A
transthoracic echocardiogram (TTE) revealed a 3.5 cm  2 cm
vegetation on the pacemaker wire (Figure 1), mild right ventricular
enlargement, mild mitral and pulmonary insufﬁciency, and an
ejection fraction of 50%. Blood cultures remained negative.ses. Published by Elsevier Ltd. All rights reserved.
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Figure 1. Transthoracic echocardiogram: 3.5 cm  2 cm vegetation on the
pacemaker lead and tricuspid valve protruding into the right ventricle (arrow).
[(Figure_2)TD$FIG]
Figure 2. Operative pathology at 400: (a) PAS stain and (b) GMS stain for fungus
demonstrating tissue invasion by fungal hyphae and acute-angle branching.
A.S. Kalokhe et al. / International Journal of Inf ctious Diseases 14 (2010) e1040–e1047 e1041The patient became febrile a few days into his hospital course.
Empiric vancomycin and ceftriaxone were initiated for culture-
negative endocarditis, but fevers persisted. On day 9 of his hospital
stay he underwent surgical extraction of the pacemaker and leads.
Although the operative mortality of this procedure is known to be
high, it was decided the beneﬁt outweighed the risk of emboliza-
tion with medical management alone. Intraoperatively, invasion
by the vegetation of the right atrium, tricuspid valve, interatrial
septum, and superior vena cava was noted, and these areas were
debulked. There was no indication at that point for a pacemaker,
therefore it was not reimplanted. Operative pathology revealed
tissue invasion by branching fungal hyphae (Figure 2) and several
operative cultures grew pure cultures of A. fumigatus. Antibiotics
were changed to intravenous voriconazole. On hospital day 17 he
was discharged home on indeﬁnite suppression with oral
voriconazole. The galactomannan antigen assay (Bio-Rad Labora-
tories, Hercules, California), sent while on antifungal therapy, was
positive (index = 0.94; positive reference cut-off: index 0.5). The
1!3-b-D-glucan assay was not performed. At 6-month follow-up
he continued to do well, had gained weight, and clinically had had
no apparent recurrence of Aspergillus disease or progression of
MDS. It is anticipated that he will remain on voriconazole
indeﬁnitely.
3. Prevalence
Aspergillus species cause approximately 20–30% of all fungal
endocarditis cases.1,2 The proportion of fungal endocarditis caused
by Aspergillus was similar in 1965–1971 (18/64 or 28%) and 1988–
1995 (14/58 or 24%), suggesting that the prevalence of Aspergillus
did not change signiﬁcantly between 1965 and 1995.1 The ratio of
Aspergillus to Candida (1:2) has also remained constant over the
last three decades.1 A recent review of fungal endocarditis between
1995 and 2000 yielded 152 cases of fungal endocarditis, 28 (18%) of
which were caused by Aspergillus.2 The majority of cases were
caused by A. fumigatus (54%), followed by Aspergillus terreus (18%),
Aspergillus niger (7%), and Aspergillus ﬂavus (7%).
Aspergillus species have also been associated with CDRIE. A
retrospective review of all infected cardiac devices at the Mayo
Clinic between 1991 and 2003 found 44 patients who met the
deﬁnition of CDRIE; 75% of these cases of CDRIE were associated
with pacemakers and 25% with automated implantable cardiac
deﬁbrillators. Fungal infectionswere demonstrated in only three of
the 44 patients with CDRIE, two of which were Aspergillus (5% of
all CDRIE cases).3 A similar retrospective study of infections among
33 patients with pacemaker endocarditis was performed in Paris,
France between 1988 and 1996.4 In this study, two of 33 patientshad fungal endocarditis, one case of which was caused by
Aspergillus (3% of CDRIE cases).
4. Risk factors
A review of the literature indicates that most patients with
Aspergillus endocarditis are male and possess a predisposing
condition.2,5,6 Pierrotti and Baddour assessed risk factors for mold-
related endocarditis among 39 patients, the majority of which was
caused by Aspergillus, and found an association with underlying
cardiac abnormalities (41%), prosthetic valves (39%), malignancy
(18%), solid-organ transplants (18%), and bonemarrow transplants
(18%).2 Woods et al. reported steroid treatment (55%), prolonged
antibiotic exposure (31%), hematological malignancy (28%), and
chemotherapy and cytotoxic therapy (28%) as the most common
predisposing factors for Aspergillus endocarditis in 29 patients.5
Among children, congenital heart disease appears to be the most
common risk factor, accounting for 67% of cases in one pediatric
series of 15 patients.6
In our patient, the major predisposing conditions were the
evolvingMDS and previous pacemaker. He had not received recent
immunosuppressive therapy and was not known to have
congenital heart disease.
5. Literature review of Aspergillus endocarditis
We conducted a Medline search for cases of Aspergillus
endocarditis using search terms ‘Aspergillus’ and ‘endocarditis’
Table 1
Aspergillus endocarditis cases reported in the medical literature between 1950 and 2009
Ref. Age/
sex
Co- morbidities Initial
presentation
Valve
involved
Complications Diagnostic modality Species Surgical
treat-
ment
Antifungal
treatment
Duration of
treatment
Outcome
17 34/M AVR Dyspnea, chest
pain, STEMI, RCA
thrombosis
Aortic Emboli to the brain
and spleen;
endophthalmitis
Aortic root culture fumigatus Yes Voriconazole,
liposomal
amphotericin
Not documented Survived
18 19/F CF, ABPA lung
transplant
New murmur,
ankle edema,
decline in FEV1
Aortic Aortic root abscess Mitral valve culture fumigatus Yes Voriconazole 6 weeks Died 14
months later
with valve
abscess
18 24/F CF, ABPA lung
transplant
Right eye pain and
vision loss
Mitral Endophthalmitis
and mesenteric
emboli
Valve culture fumigatus Yes Voriconazole 5 days (continued
until death)
Died 5 days
after surgery
19 58/M COPD, steroids Abdominal pain,
amaurosis fugax
Mitral Mesenteric and
renal artery emboli
Valve pathology and
culture, blood
culture
fumigatus Yes Voriconazole 45 days (continued
until death)
Died 45 days
after surgery
20 57/M COPD, IPF, lung
transplant,
Aspergillus in
explanted lung
Chest pain, STEMI,
LAD thrombosis
Mitral Emboli to LAD Valve pathology and
culture
fumigatus Yes Caspofungin,
amphotericin
6 weeks Survived
21 17/M Aplastic anemia,
steroids
Fever, lobar
pneumonia with
nodules, pleural
effusion
Mitral Emboli to the brain Lung nodule
pathology
Not speciﬁed No Amphotericin,
liposomal
amphotericin
5 weeks (continued
until death)
Died after 5
weeks
21 31/F Aplastic anemia,
steroids
Abdominal pain
and right arm
weakness
Mitral,
aortic
Emboli to the brain,
lung, kidney, and
spleen
Skin nodule
pathology and
culture
fumigatus No Amphotericin,
liposomal
amphotericin
69 days Died after 69
days
22 29/M IVDU, S. mitis
endocarditis
Focal seizure
involving left arm
Aortic Emboli to the brain,
eye, and femoral
artery
Vitreous culture fumigatus Yes Amphotericin,
anidulafungin,
voriconazole
2 years+ Survived
23 34/M IVDU, AIDS Fever Mitral Emboli to the brain
and LAD
Post-mortem skin,
lymph node,
pericardial effusion
pathology/ culture
fumigatus N/A Died before
initiation of
treatment
Died prior to
antifungal
treatment
Died within
a few days
24 34/M Subaortic
membrane
excision
Acute onset
bilateral lower
extremity pain
Aortic Emboli to femoral
artery
Culture of femoral
artery thrombus
terreus Yes Amphotericin 1 month+
(continued until
death)
Died within
1 month
24 45/M MVR Fever, TIA, left
hemiparesis
Mitral,
aortic
Emboli to the brain
and femoral artery
Culture of femoral
artery thrombus
ﬂavus Yes Amphotericin 17 days (continued
until death)
Died after 17
days
25 28/M AVR Fever, diplopia,
back pain
Aortic Periaortic abscess,
emboli to the iliac,
hepatic, and renal
arteries
Aortic pathology and
culture
fumigatus Yes Amphotericin 15 days (continued
until death)
Died after 15
days
25 56/M AVR Fever, newmurmur Aortic Emboli to the brain,
perivalvular
abscess
Post-mortem
coronary cusp
pathology
Not speciﬁed Yes Died prior to
initiation of
treatment
Died prior to
antifungal treatment
Died after 7
days
25 50/M AVR Fever, weight loss Aortic Emboli to the brain;
aortic abscess and
pseudo-aneurysm
Aortic valve
pathology and
culture
niger Yes Amphotericin,
itraconazole
2 months (continued
until death)
Died after 2
months
26 35/M IVDU, AIDS Fever, newmurmur Tricuspid Pulmonary emboli;
RBBB
Post-mortem valve
pathology and
culture
fumigatus No No antifungal Died prior to
antifungal treatment
Died after 5
days
26 31/M IVDU Fever Aortic Emboli to the iliac
arteries and brain
Iliac thrombus
culture
niger No Amphotericin 5 days (continued
until death)
Died after 5
days
26 39/M IVDU, AIDS Fever, dyspnea Aortic Cardiogenic shock Post-mortem heart
valve pathology
Not speciﬁed No Fluconazole 4 days (continued
until death)
Died after 4
days
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27 52/F Diabetes, renal
transplant,
pacemaker
Left eye visual loss,
uveitis, arthralgias
Mitral,
aortic
Emboli to the eye,
brain, pulmonary
artery, colon
Post-mortem heart
valve pathology/
culture
fumigatus No Amphotericin 12 days (continued
until death)
Died after 12
days
28 35/F SLE,
enterococcal
MV endocarditis
Fever, mitral
regurgitation,
respiratory failure
Mitral Mitral
regurgitation
Post-mortem valve
pathology and
culture
fumigatus N/A None Died prior to
antifungal
treatment
Died after 2
weeks
29 64/M Heart transplant Diplopia, palmar
nodule
Aortic Emboli to the eye;
valvular abscess
Vitreous culture fumigatus Yes Amphotericin,
voriconazole
Not documented Survived
5 19/M Liver transplant Hypotension, DIC,
RBBB
Tricuspid Myocardial
abscess;
pulmonary emboli
Post-mortem lung
and valve pathology/
culture
ﬂavus No Amphotericin 10 days Died prior to
diagnosis
30 54/F MVR Fever, back pain,
lower extremity
paresthesias
Mitral Emboli to the iliac
and hypogastric
arteries
Pathology from iliac
artery thrombus
ﬂavus Yes Amphotericin,
ﬂucytosine
Not documented Survived
31 41/M MVR, bacterial
endocarditis
Fever, weakness Mitral Congestive heart
failure
Post-mortem valve
culture/ pathology
fumigatus N/A Died prior to
initiation of
treatment
Died prior to
antifungal
treatment
Died
32 8 mo/F Liver transplant Dyspnea Mitral None Blood Aspergillus
PCR and Ag, tracheal
culture
fumigatus No Fluconazole
prophylaxis,
voriconazole,
caspofungin,
amphotericin
Chronic
voriconazole
suppression
Survived
33 74/F HTN, NIDCM ICD site infection ICD lead None ICD site drainage,
generator, and lead
culture
ﬂavus Yes Voriconazole 6 months Survived
34 52/M DM, kidney–
pancreas
transplant
Fever, hypoxia,
hypotension
Tricuspid Congestive heart
failure, pulmonary
emboli
Blood GM, valve
culture
fumigatus Yes Caspofungin,
voriconazole,
inhaled
amphotericin
63 days (continued
until death)
Died 61 days
after surgery
35 53/M Heart transplant Altered mental
status
Mitral Endophthalmitis,
cerebral emboli,
cardiac tamponade
Blood GM,
respiratory culture
fumigatus Yes Voriconazole,
caspofungin,
liposomal
amphotericin
174 days (continued
until death)
Died 169
days after
surgery
36 71/M PM, CASHD, SVC
syndrome
Fever, chest pain,
hypoxia
PM lead,
tricuspid
and aortic
valves
Cerebral, renal, and
pulmonary emboli
Post-mortem lead
vegetation culture
and pathology
fumigatus No amphotericin 7 days (continued
until death)
Died after 7
days
37 66/F HTN, PM, SSS Chest pain, dyspnea PM lead Pulmonary emboli Lead vegetation
culture
Not speciﬁed Yes Liposomal
amphotericin,
itraconazole
43 weeks Survived
38 39/M Alcoholic
cirrhosis
Fever, syncope,
lower extremity
pain
Mitral,
aortic
Liver, kidney,
cerebral, spleen,
myocardial, and
aortic saddle
emboli, arrhythmia
Aortic embolus
pathology and
culture
fumigatus Yes Amphotericin 12 days (continued
until death)
Died after 12
days
39 41/M AVR Acute ischemia
lower extremity
Mitral,
aortic
Lower extremity
emboli
Lower extremity
embolus pathology
and culture
ustus Yes Amphotericin 2 months Survived
39 48/M AVR Acute ischemia
lower extremity
Aortic Lower extremity
emboli; aortic
outﬂow tract
obstruction
Lower extremity
embolus and valve
culture
Not speciﬁed No No antifungal Died prior to
antifungal
treatment
Died prior to
diagnosis
40 13/F MVR Fever, lower
extremity ischemia
Mitral Cerebral, lower
extremity emboli,
arrhythmia
Mitral valve
pathology and
culture
ﬂavus Yes Amphotericin 10 days (continued
until death)
Died after 10
days
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Table 1 (Continued )
Ref. Age/
sex
Co- morbidities Initial
presentation
Valve
involved
Complications Diagnostic modality Species Surgical
treat-
ment
Antifungal
treatment
Duration of
treatment
Outcome
41 12/F TOF, PVR, VSD
repair, tricuspid
valve
annuloplasty
Fever Tricuspid,
pulmonic
Tricuspid valve
obstruction
Tricuspid valve
pathology and
culture
ﬂavus Yes None Died prior to
antifungal
treatment
Died prior to
diagnosis
42 63/M AVR Orthopnea, night
sweats, superﬁcial
thrombo-phlebitis
Aortic Cerebral emboli Post-mortem aortic
valve culture and
pathology
niger No None Died prior to
antifungal
treatment
Died prior to
diagnosis
43 60/M CABG Chest and
abdominal pain,
fever
Aortic Congestive heart
failure, annular
abscess, aortitis
Aortic valve
pathology and
culture
clavatus Yes Amphotericin 16 days
(continued
until death)
Died 16 days
after surgery
44 66/M AVR Acute visual loss,
fever, anorexia
Aortic, mitral Aortic root abscess
and pseudo-
aneurysm, renal,
IMA, and cerebral
emboli
Aortic valve
pathology and
culture
fumigatus Yes Amphotericin 4 weeks
(continued
until death)
Died 4weeks
after surgery
45 60/F ALL Fever, anorexia Mitral Mitral
regurgitation, iliac,
splenic, renal, and
aortic emboli
Blood culture, mitral
valve culture and
pathology
terreus Yes Amphotericin 7 days
(continued
until death)
Died 6 days
after surgery
46 44/M MVR Fever, arthralgias Aortic IVS abscess,
cerebral emboli,
arrhythmia, and
aortic ﬁstula
Mitral valve culture
and pathology
niger Yes Amphotericin,
itraconazole
6 months Survived
47 57/M MVR Fever Mitral None Mitral valve culture
and pathology
niger Yes Amphotericin,
itraconazole
1 year Survived
48 32/M Renal transplant Lumbago Mitral Renal, iliac, and
common femoral
artery emboli
Embolus culture and
pathology
fumigatus No Amphotericin 2 days
(continued
until death)
Died 2 days
into
treatment
49 11/M AML Necrotic lesion on
nose
Mitral,
tricuspid
Possible pulmonary
invasive
aspergillosis
Nose biopsy culture
and pathology
ﬂavus No Liposomal
amphotericin
(high dose)
Not speciﬁed Survived
50 31/M Lung transplant,
CF
Skin nodules, hip
pain, upper
extremity ischemia
Mitral Recurrent upper
and lower
extremity emboli,
mitral
regurgitation
Skin nodule and
brachial artery
embolus pathology,
culture of hip
arthrocentesis
fumigatus No Liposomal
amphotericin,
itraconazole
17 weeks
(continued
until death)
Died after 17
weeks
51 53/F AVR Fever, upper
extremity
monoparesis
Aortic Aortic aneurysm,
cerebral emboli
Aortic valve
pathology and
culture
niger Yes Amphotericin,
itraconazole,
liposomal
amphotericin
70 days Died 3
months after
diagnosis
52 55/M ICD, CASHD Fever, weight loss ICD lead and
tricuspid valve
Tricuspid
regurgitation,
pulmonary emboli
ICD and tricuspid
valve pathology and
culture
fumigatus Yes Liposomal
amphotericin,
itraconazole,
voriconazole
Not speciﬁed Survived
53 61/F TTP Fever, acute
dyspnea
Mitral Mitral
regurgitation and
papillary muscle
rupture, cerebral,
splenic, and renal
emboli, IVS abscess
Mitral valve
pathology and
culture
fumigatus Yes Liposomal
amphotericin,
itraconazole
2 months
(continued until
death)
Died 2
months after
initial
surgery
54 62/M AIDS, DM, HTN Fever, dyspnea,
cough
Mitral Ventricular
arrhythmia, mitral
regurgitation,
cerebral, renal, and
adrenal emboli
Post-mortem mitral
valve pathology
Not speciﬁed No None Died prior to
antifungal
treatment
Died prior to
diagnosis
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A.S. Kalokhe et al. / International Journal of Infectious Diseases 14 (2010) e1040–e1047 e1045for January 1950 through July 2010, yielding 53 case reports, which
are summarized in Table 1. Table 1 describes the clinical
presentations, associated co-morbidities, diagnostics, treatments,
complications, and outcomes of these cases.
Over half of the 53 cases reviewed had fever (57%) or evidence
of embolic disease (53%) at initial presentation (Table 1).
Vegetations were often large and involved the mitral (26/53 or
49%) or aortic valves (24/53 or 45%), and less frequently, the
tricuspid valve (9/53 or 17%), cardiac device leads (5/53 or 9%), or
pulmonic valve (1/53 or 2%). Multi-valve involvement was seen in
21% (11/53) of cases. Complications were common and frequently
involved embolization (40/53 or 75%) to the pulmonary, ophthal-
mic, cerebral, iliac, coronary, hepatic, splenic, renal, brachial, and/
or mesenteric arteries.
Cyanotic spells are an uncommon initial manifestation of
Aspergillus endocarditis, and may represent ventilation–perfusion
mismatch or shunting due to recurrent septic pulmonary emboli.
6. Diagnosis
The diagnosis of Aspergillus endocarditis requires a high index
of suspicion. Diagnosiswas established postmortem in 11/53 (21%)
cases by our review. Blood cultures are almost always negative (51/
53 or 96%). Fungal vegetations are frequently large. The vegetation
in our patient was large (3.5 cm  2 cm) and demonstrated by TTE
without difﬁculty.
The galactomannan antigen assay can be a useful adjunctive
test to establish the diagnosis of invasive aspergillosis, but has not
been studied in the setting of endocarditis. It is more sensitive
for detecting invasive disease due to non-fumigatus Aspergillus
than. A. fumigatus (49% vs. 13%).7 False-positive results can occur
with fungal infections (i.e., histoplasmosis, blastomycosis,
cryptococcosis, and penicilliosis), as well as concomitant antibi-
otic therapy with piperacillin–tazobactam and amoxicillin–
clavulanate.8–13
Ultimately, the diagnosis requires histological and tissue
culture conﬁrmation to differentiate Aspergillus from other molds
and to determine the species. Pathology typically demonstrates
acute angle branching and septate hyphae on Gomori methena-
mine silver (GMS) or periodic acid-Schiff (PAS) stains.
7. Treatment
The treatment of Aspergillus endocarditis is largely guided by
evidence from the treatment of other forms of invasive Aspergillus
infection. Successful treatment of endocarditis requires the
combination of antifungal therapy and surgical debridement.
The recommended antifungal therapy for most invasive Aspergil-
lus infections, including Aspergillus endocarditis, is voricona-
zole.14 The superiority of voriconazole to amphotericin B
deoxycholate was demonstrated in a large, randomized controlled
trial of invasive Aspergillus infections, the majority of which
involved the lungs and sinuses (92%). Compared to amphotericin B,
voriconazole was associated with improved survival, and less
nephrotoxicity, electrolyte abnormalities, and infusion-related
events.15 Intravenous liposomal amphotericin formulations pro-
vide a second treatment option, with equal efﬁcacy and less
nephrotoxicity than amphotericin B in the treatment of invasive
Aspergillus infections.16
Finally, surgical debridement is imperative for the survival of
almost all cases of Aspergillus endocarditis. Our search of the
literature found that only 4% (2/53) of cases were treated
successfully with antifungal therapy alone. No studies have
evaluated the appropriate duration of antifungal therapy, however
most authors recommend lifelong suppressive therapy.
A.S. Kalokhe et al. / International Journal of Infectious Diseases 14 (2010) e1040–e1047e10468. Prognosis
The prognosis is poor, with only 17 of 53 reported cases (32%)
surviving the acute episode of Aspergillus endocarditis. This may
be in part because of the immunocompromised status of the hosts,
delay in diagnosis, and rapidity of embolization. Mortality
approaches 100% among those who receive medical therapy alone.
9. Summary
Aspergillus endocarditis, speciﬁcally cardiac device-related
infection, is very rare. It should be suspected in persons with
underlying hematological malignancies, recent cardiothoracic
surgery, intravenous drug use, and immunosuppression with
culture-negative endocarditis and/or systemic or pulmonary
emboli. Diagnosis ultimately requires conﬁrmation by tissue
histology and culture. The optimal treatment approach requires
aggressive surgical debridement combined with antifungal treat-
ment, usually requiring indeﬁnite therapy with voriconazole.
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